We can’t show the full text here under this license. Use the link below to read it at the source.
Obstructive Sleep Apnea: An Evolving Therapeutic Landscape with an Emerging Role for Incretin-Based Therapies
New Treatments for Obstructive Sleep Apnea Including Incretin-Based Therapies
AI simplified
Abstract
The recent approval of tirzepatide for obesity-related (OSA) represents a significant milestone in treatment options.
- Obstructive sleep apnea is characterized by repetitive airway collapse during sleep, leading to low oxygen levels and disrupted sleep.
- OSA is highly prevalent and is closely linked to obesity and an increased risk of cardiovascular disease.
- Traditional therapies, such as positive airway pressure devices, are effective but often poorly tolerated and have limited long-term cardiovascular benefits.
- Emerging therapies are being developed to target specific physiological traits affecting OSA, including arousal threshold and muscle responsiveness.
- Tirzepatide offers dual benefits by promoting weight loss and improving the severity and symptoms of OSA.
AI simplified
Key numbers
20–24 events/hour
Average AHI Reduction with Tirzepatide
Observed in patients with moderate-to-severe at 52 weeks.
15%
Average Weight Loss with Semaglutide
Compared to an average of 2.4% weight loss with placebo.
12 events/hour
Average AHI Decrease with Liraglutide
Significant decrease after 32 weeks in patients with and obesity.